Wu, J., Cheng, J., Zhu, L., Gao, Q., Lin, H., Zeng, Y., Li, Y., Li, W., An, N., Huang, L., Xiao, M., Li, D., Mu, W.

CD5 ablation enhances persistence and antitumor potency of engineered T cells by mitigating exhaustion and promoting cytotoxicity

30 de November de 2025 by Wu, J., Cheng, J., Zhu, L., Gao, Q., Lin, H., Zeng, Y., Li, Y., Li, W., An, N., Huang, L., Xiao, M., Li, D., Mu, W.

Background
While chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for certain hematologic malignancies, therapeutic resistance and disease relapse highlight the critical need to improve the durability of clinical …